Clinical Trials Logo

Vaccine clinical trials

View clinical trials related to Vaccine.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05765773 Active, not recruiting - COVID-19 Clinical Trials

An Open Comparative Study of the Effectiveness and Incomparable Study of the Immunogenicity and Safety of the Vaccine (CoviVac) for Adults Aged 60 Years and Older

Start date: July 1, 2021
Phase: Phase 2
Study type: Interventional

An Open Comprative Study of the Prophylactic Efficacy and a Non-comparative Study of the Immunogenicity and Safety of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine (CoviVac) Produced by FSBSI "Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products" for Adults Aged 60 Years and Older

NCT ID: NCT05752747 Active, not recruiting - Pain Clinical Trials

The Effect of Shotblocker and Cold Massage on Pain, Crying Time and Physiological Parameters in Babies

Start date: June 9, 2022
Phase: N/A
Study type: Interventional

The aim of this study is to determine the effect of ShotBlocker© and cold massage on pain, crying time and physiological parameters during DaBT-IPA-Hib vaccine administration in 2-6 months old babies.

NCT ID: NCT05715918 Active, not recruiting - Vaccine Clinical Trials

Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19 of Children at the Age of 12-17 Years Inclusive"

Start date: April 1, 2022
Phase: Phase 3
Study type: Interventional

Randomized, double-blind, placebo controlled, multi-center clinical trials of the tolerability, safety and immunogenicity of the inactivated whole-virion concentrated purified vaccine against COVID-19, manufactured by FSBSI "Chumakov FSC R&D IBP RAS", of childrens aged 12-17" (Clinical trials, phase III). Study purpose is to assess the tolerability, safety and immunogenicity of the inactivated whole-virion concentrated purified coronavirus vaccine of chidrens aged 12-17

NCT ID: NCT05099965 Active, not recruiting - HIV Infections Clinical Trials

Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)

Start date: November 2, 2021
Phase: Phase 2
Study type: Interventional

Participants will be randomized in a 2:1 ratio to receive either two injections of CMV-MVA Triplex® or placebo administered at study Entry/Day 0 and week 4. Vaccine Group: 60 participants will receive CMV-MVA Triplex® containing 5 x 10^8 plaque-forming unit (pfu) ±0.5 x 10^8 pfu of MVA Vaccine Encoding CMV Antigens by intramuscular (IM) deltoid injections. Placebo Group: 30 participants will receive a volume of placebo (7.5% Lactose in phosphate-buffered saline [PBS]) that matches the volume of the active vaccine injection by IM deltoid injections.

NCT ID: NCT04741828 Active, not recruiting - Vaccine Clinical Trials

Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian

Start date: May 3, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

Vi-DT Typhoid vaccine is a novel vaccine. This study will be done to know the long-term protection and persistent antibody by measured the antibody titer after 2,3,4 and 5 years after immunization.

NCT ID: NCT04083950 Active, not recruiting - Inflammation Clinical Trials

Induction of Gut Permeability by an Oral Vaccine

Start date: December 4, 2019
Phase: Early Phase 1
Study type: Interventional

This study evaluates the effect of an oral typhoid vaccine on disruption of the intestinal barrier and response of the immune system. Intestinal and whole-body responses will be measured in all participants before and after the vaccine.